REUTERS/Mike Brown Shares of Intercept Pharmaceuticals were up 45% shortly after the market open on Tuesday after the company on Monday announced development updates for several of its drug candidates. The company, which has a market cap of more than $5 billion, also reported second quarter earnings, posting a larger than expected quarterly loss.  Intercept is a biopharmaceutical company focused on the development of liver disease treatments. Intercept shares, which were halted ahead of the company's announcement on Monday afternoon, were up nearly 250% year-to-date as of Monday's close, with the stock nearly quadrupling in one day on January 9 after the company stopped its FLINT trial of obeticholic acid for the treatment of nonalcoholic steatohepatitis, or NASH, due to "early efficacy." In its 10-Q filed with the SEC on Monday afternoon, Intercept outlined new developments for its FLINT trial.  On Monday, the company also gave the following updates on its development programs: TheStreet.com's biotech reporter Adam Feuerstein broke down the results last night, writing that the rally in shares, "reflects a sense of relief that OCA head into a registration-worthy phase III study next year with less risk."   FREE AppDownload
